Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first…
Tag: fabhalta®
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first…
